# Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the PREV-HAP Study

> **NCT04793568** · PHASE2 · UNKNOWN · sponsor: **Nantes University Hospital** · enrollment: 109 (actual)

## Conditions studied

- Critically Ill Patients

## Interventions

- **DRUG:** Recombinant Interferon gamma 1b (IMUKIN®)
- **DRUG:** Recombinant Interferon gamma 1b placebo

## Key facts

- **NCT ID:** NCT04793568
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-29
- **Primary completion:** 2021-11-07
- **Final completion:** 2023-06
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2022-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04793568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04793568, "Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the PREV-HAP Study". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04793568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*